Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nuclear factor kappa-light-chain-enhancer of activated B cells subunit p65 (NF-κB p65 or RELA) is a transcription factor crucial for immune responses, inflammation, cell survival, and proliferation. It is part of the NF-κB complex, which is involved in various signaling pathways and is activated by diverse stimuli such as cytokines, stress, and bacterial or viral antigens. Misregulation of NF-κB has been linked to cancer, autoimmune diseases, and inflammatory conditions.
Drugs targeting NF-κB p65 typically work by inhibiting its activity, which can reduce inflammation and immune response.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nuclear factor kappa-light-chain-enhancer of activated B cells subunit p65 (NF-κB p65 or RELA).